- Report
- June 2024
- 200 Pages
Global
From €7141EUR$7,950USD£6,098GBP
- Report
- January 2024
- 200 Pages
Japan
From €5165EUR$5,750USD£4,410GBP
- Report
- January 2024
- 100 Pages
Japan
From €1707EUR$1,900USD£1,457GBP
- Report
- September 2024
- 82 Pages
Japan
From €2672EUR$2,975USD£2,282GBP
€3144EUR$3,500USD£2,685GBP
- Report
- April 2024
- 180 Pages
Global
From €3436EUR$3,825USD£2,934GBP
€4042EUR$4,500USD£3,452GBP
- Report
- December 2022
- 112 Pages
Global
From €3436EUR$3,825USD£2,934GBP
€4042EUR$4,500USD£3,452GBP
- Drug Pipelines
- May 2023
- 151 Pages
Global
From €13469EUR$14,995USD£11,501GBP
- Report
- November 2022
- 330 Pages
Global
From €3593EUR$4,000USD£3,068GBP
- Report
- March 2023
- 1355 Pages
Global
From €2246EUR$2,500USD£1,918GBP
- Report
- May 2020
- 218 Pages
Global
From €13469EUR$14,995USD£11,501GBP
- Report
- May 2020
- 47 Pages
Global
From €3588EUR$3,995USD£3,064GBP
- Report
- April 2024
- 80 Pages
Russia
From €1347EUR$1,500USD£1,151GBP
- Report
- April 2024
- 80 Pages
Saudi Arabia
From €1347EUR$1,500USD£1,151GBP
- Report
- April 2024
- 80 Pages
South Korea
From €1347EUR$1,500USD£1,151GBP
From €1347EUR$1,500USD£1,151GBP
- Report
- April 2024
- 80 Pages
United Kingdom
From €1347EUR$1,500USD£1,151GBP
- Report
- April 2024
- 80 Pages
United States
From €1347EUR$1,500USD£1,151GBP
- Report
- April 2024
- 80 Pages
Vietnam
From €1347EUR$1,500USD£1,151GBP
- Report
- April 2024
- 80 Pages
Argentina
From €1347EUR$1,500USD£1,151GBP
- Report
- April 2024
- 80 Pages
Brazil
From €1347EUR$1,500USD£1,151GBP

The Alzheimer's Disease Drugs market is a sector of the pharmaceutical industry that focuses on the development and sale of drugs to treat Alzheimer's Disease. Alzheimer's Disease is a progressive neurological disorder that affects memory, thinking, and behavior. It is the most common form of dementia, and is estimated to affect over 5 million people in the United States alone.
The Alzheimer's Disease Drugs market is highly competitive, with many companies vying for a share of the market. Companies in the market include Eli Lilly, Pfizer, Novartis, Merck, and Johnson & Johnson. These companies are developing and marketing drugs to treat Alzheimer's Disease, such as cholinesterase inhibitors, memantine, and monoclonal antibodies. Additionally, many of these companies are researching and developing new treatments for Alzheimer's Disease, such as gene therapy and stem cell therapy. Show Less Read more